Real-World Efficacy and Adherence to Palbociclib in HR-Positive, HER2-Negative Advanced Breast Cancer: Insights from a Romanian Cohort
While both AI and fulvestrant remain viable options, the lack of significant differences in survival between these combinations suggests that treatment choice can be tailored to individual patient needs.
Authors
- Andrei Biţă (ORCID: https://orcid.org/0000-0003-4715-1423)
- Simona Ruxandra Volovăț (ORCID: https://orcid.org/0000-0001-7084-6333)
- Cristian Virgil Lungulescu (ORCID: https://orcid.org/0000-0003-3578-3562)
- Georgiana-Cristiana Camen
- Adina Turcu-Ştiolică (ORCID: https://orcid.org/0000-0003-1374-276X)
- Sandra Alice Buteică
- Marina-Daniela Dimulescu
- Mihaela-Simona Naidin (ORCID: https://orcid.org/0000-0001-9173-2976)
- Venera-Cristina Dinescu
- Tradian-Ciprian Berisha
Institutions
- University of Medicine and Pharmacy of Craiova (RO)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3390/cancers16244161
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42